Filter Results:
(924)
Show Results For
- All HBS Web
(924)
- People (2)
- News (70)
- Research (773)
- Events (1)
- Multimedia (2)
- Faculty Publications (664)
Show Results For
- All HBS Web
(924)
- People (2)
- News (70)
- Research (773)
- Events (1)
- Multimedia (2)
- Faculty Publications (664)
- January 1998 (Revised February 2006)
- Background Note
Creating Competitive Advantage
By: Pankaj Ghemawat and Jan W. Rivkin
A firm such as Schering-Plough that earns superior, long-run financial returns within its industry is said to enjoy a competitive advantage over its rivals. This note examines the logic of how firms create competitive advantage. It emphasizes two themes: First, to... View Details
Keywords: Competitive Advantage; Competitive Strategy; Management; Business Strategy; Growth and Development Strategy; Innovation Strategy; Management Practices and Processes; Value Creation; Pharmaceutical Industry
Ghemawat, Pankaj, and Jan W. Rivkin. "Creating Competitive Advantage." Harvard Business School Background Note 798-062, January 1998. (Revised February 2006.)
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
Keywords: Health Disorders; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- Web
Strategy - Doctoral
Strategy The doctoral program in Strategy encourages students to pursue multi-disciplinary research that utilizes multiple methodologies—quantitative, as well as qualitative—to study how companies and industries around the world develop... View Details
- June 2024 (Revised December 2024)
- Case
Lana Ghanem: Pushing the Boundaries of Health Care through Venture Capital
By: Joshua D. Margolis and Ahmed Dahawy
Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Health Industry; Health Industry; Jordan
Margolis, Joshua D., and Ahmed Dahawy. "Lana Ghanem: Pushing the Boundaries of Health Care through Venture Capital." Harvard Business School Case 424-075, June 2024. (Revised December 2024.)
- 14 Aug 2007
- First Look
First Look: August 14, 2007
in West Africa, 1950-1970 Author:Stephanie Decker Periodical:Business History Review 81 (spring 2007): 59-86 Abstract Development, modernity, and industrialization became dominant themes in corporate advertising in Africa in the 1950s and... View Details
Keywords: Martha Lagace
- October 2019
- Supplement
Impax Laboratories: Executing Accretive Transactions (A)
By: Benjamin C. Esty and Daniel Fisher
Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
- October 2019
- Case
Impax Laboratories: Executing Accretive Acquisitions (A)
By: Benjamin C. Esty and Daniel Fisher
Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Acquisitions (A)." Harvard Business School Case 220-030, October 2019.
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
- May 2021
- Case
The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease
By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory... View Details
Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Public Administration Industry; United States
Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.
- January 2017
- Case
Danaher Corporation, 2007–2017
By: John R. Wells and Gabriel Ellsworth
On July 2, 2016, Danaher Corporation completed the spinoff of Fortive Corporation. The previous day, Danaher’s stock price had reached an all-time high. In 2015, Danaher had decided to split off its test and measurement, fuel and fleet management, and automation... View Details
Keywords: Danaher; Fortive; Larry Culp; Beckman Coulter; Pall; Life Sciences; Diagnostics; Environmental Operations; Water Management; Dental; Testing; Measurement; Fuel; Fleet Management; Automation; Toolmaking; Tools; Disease Management; Continuous Improvement; Toyota Production System; Divestiture; Spinoffs; Spin-off; Networks; Acquisition; Mergers and Acquisitions; Business Conglomerates; Business Divisions; Business Subsidiaries; Business Units; Business Growth and Maturation; Business Model; For-Profit Firms; Joint Ventures; Restructuring; Engineering; Chemicals; Construction; Machinery and Machining; Profit; Revenue; Globalized Firms and Management; Multinational Firms and Management; Health; Health Care and Treatment; Health Disorders; Medical Specialties; Business History; Job Cuts and Outsourcing; Business or Company Management; Growth and Development Strategy; Management Analysis, Tools, and Techniques; Management Practices and Processes; Management Succession; Management Systems; Resource Allocation; Market Entry and Exit; Measurement and Metrics; Logistics; Business Processes; Organizational Change and Adaptation; Public Ownership; Problems and Challenges; Science; Genetics; Natural Environment; Wastes and Waste Processing; Science-Based Business; Opportunities; Strategy; Adaptation; Business Strategy; Competition; Competitive Strategy; Competitive Advantage; Consolidation; Corporate Strategy; Diversification; Expansion; Technology; Software; Technology Networks; Technology Platform; Value; Valuation; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; Aerospace Industry; United States; District of Columbia
Wells, John R., and Gabriel Ellsworth. "Danaher Corporation, 2007–2017." Harvard Business School Case 717-464, January 2017.
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Pharmaceutical Industry; United States; United Kingdom; Australia; Germany; Europe
Krieger, Joshua Lev, Tom Nicholas, and Matthew Preble. "The 'Wonder Drug' That Killed Babies." Harvard Business School Case 818-044, November 2017.
- 15 May 2007
- First Look
First Look: May 15, 2007
the industry and dominated it for nearly 20 years, the well-respected company faces a bevy of new entrants from the banking, mortgage finance, and insurance sectors. In particular, management must decide how to respond to an aggressive... View Details
Keywords: Martha Lagace
- Web
Hiring Organizations
Partners AllWin Alpaca Real Estate Alphabroder Alpine Investors Alterra Capital Partners Altitude AI Altos Ventures Alumni Ventures Amazon Amazon Web Services - AWS Ambit Partners American Express American Industrial Partners Amex... View Details
- 16 Aug 2011
- Working Paper Summaries
Managing Political Risk in Global Business: Beiersdorf 1914-1990
Regina E. Herzlinger
Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration at the Harvard Business School. She was the first woman to be tenured and chaired at Harvard Business School and serve on many established and start-up corporate health care/medical... View Details
- 23 Jul 2001
- Research & Ideas
How Relationships are Building Biotech
How does an industry get born? To answer that question, it helps to turn the microscope on one fairly new industry: biotechnology. A still further way to get inside this question, according to HBS professor Monica C. Higgins, is to take a... View Details
Keywords: by Martha Lagace & Mallory Stark
Karim R. Lakhani
Karim R. Lakhani is the Dorothy & Michael Hintze Professor of Business Administration at the Harvard Business School. He specializes in technology management, innovation, digital transformation and artificial... View Details
Keywords: information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry; information technology industry
- 10 Oct 2007
- First Look
First Look: First Look: October 10
spending associated with the redemption of such a coupon is focused on "marginal" grocery items, or grocery items that a customer does not typically buy. Download the paper: http://www.hbs.edu/research/pdf/08-024.pdf The Causes and Consequences of View Details
Keywords: Martha Lagace
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)